title: Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population.
abstract: Extra-nodal NK/T-cell lymphoma, nasal type (EN-NK/TCL-NT), is rare in the Western world. We launched the current single-institutional retrospective study with Institutional Review Board approval to better understand the disease. 43 EN-NK/TCL-NT patients treated from 1996 to 2014 were analyzed, including 10 (23%) Asians and 33 (76%) non-Asians. 19/26 (73%) early-stage patients received short-course chemotherapy followed by radiotherapy. 14/17 (82%) advanced-stage patients received primary chemotherapy. Complete response rate was significantly higher in the modified-SMILE group than the accelerated-CHOP group (80% vs. 30%, p = 0.015). The 2-year overall survival (OS) and progression-free survival (PFS) were 60% and 40%, respectively. Early-stage disease had significantly higher 2-year OS (87% vs. 21%) and PFS (56% vs.18%) than advanced-stage (p < 0.001). Ethnicity had no prognostic difference. EN-NK/TCL-NT in non-Asians shared similar disease characteristics and treatment outcomes with Asians. Most early-stage patients have achieved durable remissions. Management of advanced-stage disease remains challenging, with frequent progression and high mortality.
authors.affiliation: a Department of Radiation Oncology , Memorial Sloan Kettering Cancer Center , New York , NY , USA ;|b Department of Radiation Oncology , Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China ;
authors.forename: Shunan
authors.initials: S
authors.lastname: Qi
authors.affiliation: a Department of Radiation Oncology , Memorial Sloan Kettering Cancer Center , New York , NY , USA ;
authors.forename: Joachim
authors.initials: J
authors.lastname: Yahalom
authors.affiliation: c Department of Epidemiology and Biostatistics , Memorial Sloan Kettering Cancer Center , New York , NY , USA ;
authors.forename: Meier
authors.initials: M
authors.lastname: Hsu
authors.affiliation: a Department of Radiation Oncology , Memorial Sloan Kettering Cancer Center , New York , NY , USA ;
authors.forename: Monica
authors.initials: M
authors.lastname: Chelius
authors.affiliation: d Lymphoma Service, Department of Medicine , Memorial Sloan Kettering Cancer Center , New York , NY , USA.
authors.forename: Matthew
authors.initials: M
authors.lastname: Lunning
authors.affiliation: d Lymphoma Service, Department of Medicine , Memorial Sloan Kettering Cancer Center , New York , NY , USA.
authors.forename: Alison
authors.initials: A
authors.lastname: Moskowitz
authors.affiliation: d Lymphoma Service, Department of Medicine , Memorial Sloan Kettering Cancer Center , New York , NY , USA.
authors.forename: Steven
authors.initials: S
authors.lastname: Horwitz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell / Q000175:diagnosis / Q000453:epidemiology* / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D044382:Population Groups / Q000706:statistics & numerical data*; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D018426:SEER Program; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology / Q000208:ethnology; D055815:Young Adult
keywords: Drug therapy; SMILE; ethnology; extranodal NK-T-cell lymphomas; radiotherapy